Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 480

1.
2.

The implications of target saturation for the use of drug-target residence time.

de Witte WEA, Danhof M, van der Graaf PH, de Lange ECM.

Nat Rev Drug Discov. 2018 Dec 28;18(1):82-84. doi: 10.1038/nrd.2018.234. No abstract available.

PMID:
30591716
3.

Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.

Mochel JP, Teng CH, Peyrou M, Giraudel J, Danhof M, Rigel DF.

Eur J Pharm Sci. 2019 Feb 1;128:103-111. doi: 10.1016/j.ejps.2018.11.037. Epub 2018 Nov 30.

PMID:
30508581
4.

The future of drug development: the paradigm shift towards systems therapeutics.

Danhof M, Klein K, Stolk P, Aitken M, Leufkens H.

Drug Discov Today. 2018 Dec;23(12):1990-1995. doi: 10.1016/j.drudis.2018.09.002. Epub 2018 Sep 10. Review.

5.

Correction to: Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models.

de Witte WEA, Rottschäfer V, Danhof M, van der Graaf PH, Peletier LA, de Lange ECM.

J Pharmacokinet Pharmacodyn. 2018 Oct;45(5):763. doi: 10.1007/s10928-018-9604-y.

6.

In vitro and in silico analysis of the effects of D2 receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations.

de Witte WEA, Versfelt JW, Kuzikov M, Rolland S, Georgi V, Gribbon P, Gul S, Huntjens D, van der Graaf PH, Danhof M, Fernández-Montalván A, Witt G, de Lange ECM.

Br J Pharmacol. 2018 Nov;175(21):4121-4136. doi: 10.1111/bph.14456. Epub 2018 Sep 21.

7.

Authors' Reply to Standing et al.: "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials".

van Dijkman SC, de Jager NCB, Rauwé WM, Danhof M, Della Pasqua O.

Clin Pharmacokinet. 2018 Nov;57(11):1473-1475. doi: 10.1007/s40262-018-0698-6. No abstract available.

PMID:
30027512
8.

Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models.

de Witte WEA, Rottschäfer V, Danhof M, van der Graaf PH, Peletier LA, de Lange ECM.

J Pharmacokinet Pharmacodyn. 2018 Aug;45(4):621-635. doi: 10.1007/s10928-018-9593-x. Epub 2018 May 18. Erratum in: J Pharmacokinet Pharmacodyn. 2018 Aug 31;:.

9.

Correction to: Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials.

van Dijkman SC, de Jager NCB, Rauwé WM, Danhof M, Della Pasqua O.

Clin Pharmacokinet. 2018 Aug;57(8):1055-1056. doi: 10.1007/s40262-018-0660-7.

PMID:
29691814
10.

Extending a Systems Model of the APP Pathway: Separation of β- and γ-Secretase Sequential Cleavage Steps of APP.

van Maanen EMT, van Steeg TJ, Ahsman MJ, Michener MS, Savage MJ, Kennedy ME, Kleijn HJ, Stone J, Danhof M.

J Pharmacol Exp Ther. 2018 Jun;365(3):507-518. doi: 10.1124/jpet.117.244699. Epub 2018 Mar 21.

PMID:
29563326
11.

Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments.

Calvier EAM, Krekels EHJ, Yu H, Välitalo PAJ, Johnson TN, Rostami-Hodjegan A, Tibboel D, van der Graaf PH, Danhof M, Knibbe CAJ.

CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):175-185. doi: 10.1002/psp4.12273. Epub 2018 Feb 5.

12.

Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials.

van Dijkman SC, de Jager NCB, Rauwé WM, Danhof M, Della Pasqua O.

Clin Pharmacokinet. 2018 Aug;57(8):1039-1053. doi: 10.1007/s40262-017-0614-5. Erratum in: Clin Pharmacokinet. 2018 Apr 25;:.

PMID:
29363050
13.

Modeling of prolactin response following dopamine D2 receptor antagonists in rats: can it be translated to clinical dosing?

Taneja A, Vermeulen A, Huntjens DRH, Danhof M, De Lange ECM, Proost JH.

Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.364.

14.

Target and Tissue Selectivity Prediction by Integrated Mechanistic Pharmacokinetic-Target Binding and Quantitative Structure Activity Modeling.

Vlot AHC, de Witte WEA, Danhof M, van der Graaf PH, van Westen GJP, de Lange ECM.

AAPS J. 2017 Dec 4;20(1):11. doi: 10.1208/s12248-017-0172-7.

PMID:
29204742
15.

Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach.

Yamamoto Y, Välitalo PA, Wong YC, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Beukers MW, Kokki H, Kokki M, Danhof M, van Hasselt JGC, de Lange ECM.

Eur J Pharm Sci. 2018 Jan 15;112:168-179. doi: 10.1016/j.ejps.2017.11.011. Epub 2017 Nov 11.

PMID:
29133240
16.

Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.

Taneja A, Della Pasqua O, Danhof M.

Eur J Clin Pharmacol. 2017 Oct;73(10):1219-1236. doi: 10.1007/s00228-017-2301-8. Epub 2017 Sep 11. Review.

17.

Predicting Drug Concentration-Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically-Based Pharmacokinetic Model.

Yamamoto Y, Välitalo PA, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Beukers MW, van den Berg DJ, Hartman R, Wong YC, Danhof M, van Hasselt JGC, de Lange ECM.

CPT Pharmacometrics Syst Pharmacol. 2017 Nov;6(11):765-777. doi: 10.1002/psp4.12250. Epub 2017 Oct 13.

18.

Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children.

van Dijkman SC, Rauwé WM, Danhof M, Della Pasqua O.

Br J Clin Pharmacol. 2018 Jan;84(1):97-111. doi: 10.1111/bcp.13400. Epub 2017 Nov 7.

19.

Individualized Dosing Algorithms and Therapeutic Monitoring for Antiepileptic Drugs.

van Dijkman SC, Wicha SG, Danhof M, Della Pasqua OE.

Clin Pharmacol Ther. 2018 Apr;103(4):663-673. doi: 10.1002/cpt.777. Epub 2017 Aug 30.

PMID:
28653352
20.

Characterizing QT interval prolongation in early clinical development: a case study with methadone.

Dubois VFS, Danhof M, Della Pasqua O.

Pharmacol Res Perspect. 2017 Jan 24;5(1):e00284. doi: 10.1002/prp2.284. eCollection 2017 Feb.

21.

Erratum to: Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations.

Yamamoto Y, Danhof M, de Lange ECM.

AAPS J. 2017 Jul;19(4):1249-1252. doi: 10.1208/s12248-017-0080-x. No abstract available.

PMID:
28488175
22.

Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations.

Yamamoto Y, Danhof M, de Lange ECM.

AAPS J. 2017 Jul;19(4):891-909. doi: 10.1208/s12248-017-0050-3. Epub 2017 Mar 9. Review. Erratum in: AAPS J. 2017 Jul;19(4):1249-1252.

PMID:
28281195
23.

Application of a systems pharmacology model for translational prediction of hERG-mediated QTc prolongation.

Gotta V, Yu Z, Cools F, van Ammel K, Gallacher DJ, Visser SA, Sannajust F, Morissette P, Danhof M, van der Graaf PH.

Pharmacol Res Perspect. 2016 Nov 17;4(6):e00270. doi: 10.1002/prp2.270. eCollection 2016 Dec.

24.

Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.

Piana C, Danhof M, Della Pasqua O.

Expert Opin Drug Metab Toxicol. 2017 May;13(5):497-511. doi: 10.1080/17425255.2017.1277203. Epub 2017 Jan 23. Review.

PMID:
28043170
25.

Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach.

Snelder N, Ploeger BA, Luttringer O, Rigel DF, Webb RL, Feldman D, Fu F, Beil M, Jin L, Stanski DR, Danhof M.

J Pharmacol Exp Ther. 2017 Feb;360(2):356-367. doi: 10.1124/jpet.116.236208. Epub 2016 Dec 1.

PMID:
27934627
26.

Disease Systems Analysis of Bone Mineral Density and Bone Turnover Markers in Response to Alendronate, Placebo, and Washout in Postmenopausal Women.

Berkhout J, Stone JA, Verhamme KM, Danhof M, Post TM.

CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):656-664. doi: 10.1002/psp4.12135. Epub 2016 Nov 21.

27.

A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations.

Yamamoto Y, Välitalo PA, van den Berg DJ, Hartman R, van den Brink W, Wong YC, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Bakshi S, Aranzana-Climent V, Marchand S, Dahyot-Fizelier C, Couet W, Danhof M, van Hasselt JG, de Lange EC.

Pharm Res. 2017 Feb;34(2):333-351. doi: 10.1007/s11095-016-2065-3. Epub 2016 Nov 18.

28.

Translating QT interval prolongation from conscious dogs to humans.

Dubois VF, Smania G, Yu H, Graf R, Chain AS, Danhof M, Della Pasqua O; Cardiovascular Safety Project Team; TI Pharma PKPD Platform.

Br J Clin Pharmacol. 2017 Feb;83(2):349-362. doi: 10.1111/bcp.13123. Epub 2016 Oct 29.

29.

The variability in beta-cell function in placebo-treated subjects with type 2 diabetes: application of the weight-HbA1c-insulin-glucose (WHIG) model.

Duong JK, de Winter W, Choy S, Plock N, Naik H, Krauwinkel W, Visser SA, Verhamme KM, Sturkenboom MC, Stricker BH, Danhof M.

Br J Clin Pharmacol. 2017 Mar;83(3):487-497. doi: 10.1111/bcp.13144. Epub 2016 Nov 17.

30.

Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride in rats.

Taneja A, Vermeulen A, Huntjens DR, Danhof M, De Lange EC, Proost JH.

Data Brief. 2016 Aug 6;8:1433-7. doi: 10.1016/j.dib.2016.07.060. eCollection 2016 Sep.

31.

Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?

Calvier EA, Krekels EH, Välitalo PA, Rostami-Hodjegan A, Tibboel D, Danhof M, Knibbe CA.

Clin Pharmacokinet. 2017 Mar;56(3):273-285. doi: 10.1007/s40262-016-0436-x.

32.

Levofloxacin-Induced QTc Prolongation Depends on the Time of Drug Administration.

Kervezee L, Gotta V, Stevens J, Birkhoff W, Kamerling I, Danhof M, Meijer JH, Burggraaf J.

CPT Pharmacometrics Syst Pharmacol. 2016 Sep;5(9):466-74. doi: 10.1002/psp4.12085. Epub 2016 Aug 1.

33.

Pharmacotherapy in pediatric epilepsy: from trial and error to rational drug and dose selection - a long way to go.

van Dijkman SC, Alvarez-Jimenez R, Danhof M, Della Pasqua O.

Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1143-56. doi: 10.1080/17425255.2016.1203900. Epub 2016 Jul 21. Review.

PMID:
27434782
34.
35.

Understanding the Behavior of Systems Pharmacology Models Using Mathematical Analysis of Differential Equations: Prolactin Modeling as a Case Study.

Bakshi S, de Lange EC, van der Graaf PH, Danhof M, Peletier LA.

CPT Pharmacometrics Syst Pharmacol. 2016 Jul;5(7):339-51. doi: 10.1002/psp4.12098. Epub 2016 Jul 20.

36.

A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats.

Taneja A, Vermeulen A, Huntjens DRH, Danhof M, De Lange ECM, Proost JH.

Eur J Pharmacol. 2016 Oct 15;789:202-214. doi: 10.1016/j.ejphar.2016.07.005. Epub 2016 Jul 6.

PMID:
27395799
37.

In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant.

de Witte WEA, Danhof M, van der Graaf PH, de Lange ECM.

Trends Pharmacol Sci. 2016 Oct;37(10):831-842. doi: 10.1016/j.tips.2016.06.008. Epub 2016 Jul 6. Review.

PMID:
27394919
38.

Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients.

Moes DJ, Press RR, Ackaert O, Ploeger BA, Bemelman FJ, Diack C, Wessels JA, van der Straaten T, Danhof M, Sanders JS, Homan van der Heide JJ, Guchelaar HJ, de Fijter JW.

Br J Clin Pharmacol. 2016 Jul;82(1):227-37. doi: 10.1111/bcp.12946. Epub 2016 May 10.

39.

Systems pharmacology - Towards the modeling of network interactions.

Danhof M.

Eur J Pharm Sci. 2016 Oct 30;94:4-14. doi: 10.1016/j.ejps.2016.04.027. Epub 2016 Apr 27. Review.

40.

Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans.

Sahota T, Danhof M, Della Pasqua O.

Mutagenesis. 2016 May;31(3):359-74. doi: 10.1093/mutage/gev081. Epub 2016 Mar 12. Review.

PMID:
26970519
41.

Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D₂ Receptor Occupancy.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2016 May;33(5):1305-6. doi: 10.1007/s11095-016-1888-2. Epub 2016 Mar 10. No abstract available.

42.

Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid.

van Hasselt JG, Rizk ML, Lala M, Chavez-Eng C, Visser SA, Kerbusch T, Danhof M, Rao G, van der Graaf PH.

Br J Clin Pharmacol. 2016 Jun;81(6):1113-23. doi: 10.1111/bcp.12901. Epub 2016 Apr 1.

43.

Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients.

Brill MJ, Välitalo PA, Darwich AS, van Ramshorst B, van Dongen HP, Rostami-Hodjegan A, Danhof M, Knibbe CA.

CPT Pharmacometrics Syst Pharmacol. 2016 Jan;5(1):20-30. doi: 10.1002/psp4.12048. Epub 2015 Dec 18.

44.

Systems Pharmacology Analysis of the Amyloid Cascade after β-Secretase Inhibition Enables the Identification of an Aβ42 Oligomer Pool.

van Maanen EM, van Steeg TJ, Michener MS, Savage MJ, Kennedy ME, Kleijn HJ, Stone JA, Danhof M.

J Pharmacol Exp Ther. 2016 Apr;357(1):205-16. doi: 10.1124/jpet.115.230565. Epub 2016 Jan 29.

PMID:
26826190
45.

Sampling Optimization in Pharmacokinetic Bridging Studies: Example of the Use of Deferiprone in Children With β-Thalassemia.

Bellanti F, Di Iorio VL, Danhof M, Della Pasqua O.

J Clin Pharmacol. 2016 Sep;56(9):1094-103. doi: 10.1002/jcph.708. Epub 2016 Apr 1.

PMID:
26785826
46.

Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2016 Apr;33(4):1003-17. doi: 10.1007/s11095-015-1846-4. Epub 2015 Dec 30. Erratum in: Pharm Res. 2016 May;33(5):1305-6.

PMID:
26718955
47.

Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid.

Välitalo PA, Griffioen K, Rizk ML, Visser SA, Danhof M, Rao G, van der Graaf PH, van Hasselt JG.

Pharm Res. 2016 Apr;33(4):856-67. doi: 10.1007/s11095-015-1832-x. Epub 2015 Dec 1.

PMID:
26626793
48.

Model-Based Optimisation of Deferoxamine Chelation Therapy.

Bellanti F, Del Vecchio GC, Putti MC, Cosmi C, Fotzi I, Bakshi SD, Danhof M, Della Pasqua O.

Pharm Res. 2016 Feb;33(2):498-509. doi: 10.1007/s11095-015-1805-0. Epub 2015 Nov 10.

49.

Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans.

Dubois VF, de Witte WE, Visser SA, Danhof M, Della Pasqua O; Cardiovascular Safety Project Team; TI Pharma PKPD Platform.

Pharm Res. 2016 Jan;33(1):40-51. doi: 10.1007/s11095-015-1760-9. Epub 2015 Nov 9.

50.

Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients.

de Witte WE, Wong YC, Nederpelt I, Heitman LH, Danhof M, van der Graaf PH, Gilissen RA, de Lange EC.

Expert Opin Drug Discov. 2016;11(1):45-63. doi: 10.1517/17460441.2016.1100163. Epub 2015 Oct 20. Review.

PMID:
26484747

Supplemental Content

Loading ...
Support Center